Session » (1183–1199) Osteoarthritis – Clinical Poster II

Date: Monday, November 13, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

Abstract Number: 1183

CoLchicine for Treatment of OsteoArthritis of the Knee—Updated Data from a Double-blind, Placebo-controlled Trial

Abstract Number: 1184

A Wearable-Sensor for Assessment of Gait and Chair Stand Patterns in People with Knee Osteoarthritis: Validation and Responsiveness to Treatment of a Potential Digital Biomarker

Abstract Number: 1185

Soluble Buffered Alendronate After Denosumab Discontinuation in Erosive Hand OA Patients

Abstract Number: 1186

Presence of Erosions Is Not a Risk Factor for the Development of Knee OA in a Hand OA Population: The Framingham OA Study

Abstract Number: 1187

Post-hoc Analysis of Individual Questions from the Australian/Canadian Osteoarthritis Hand Index from a Randomized, Double-blind, Placebo-controlled Trial of Patients with Hand OA

Abstract Number: 1188

Development of a Method to Isolate Functional Mitochondria and Assess Their Functionality and Integration in Joint Tissues: In Vitro and in Vivo Models

Abstract Number: 1189

Evaluating Neuropathic and Nociplastic Pain in Patients with Hip and Knee Osteoarthritis

Abstract Number: 1190

Worsening of Pain as Perceived by Patients Is Not Reflected by an Annual Standardized Questionnaire

Abstract Number: 1191

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dosing, Ascending-Dose Study Evaluating the Safety, Tolerability and Pharmacokinetics of XG004 Applied Topically in Participants with Osteoarthritis of the Knee

Abstract Number: 1192

Autoimmune Thyroid Disease Associates with Symptomatic Hand Osteoarthritis in Older Persons in the Third National Health and Nutrition Examination Survey

Abstract Number: 1193

The Association of Peak Forces and Loading Rates During Walking with MRI-Based Structural Worsening of the Knee: The Multicenter Osteoarthritis Study

Abstract Number: 1194

Extent of Subregional Involvement of Subchondral Bone Marrow Lesions in Incident Knee OA Is Associated with Weight-Bearing Knee Pain

Abstract Number: 1195

Relationship of Depth-Specific Subchondral Bone Mineral Density to MRI Cartilage Worsening: The Multicenter Osteoarthritis Study

Abstract Number: 1196

Association of Long-Term Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) with Worsening Symptoms and Structural Changes of Knee Osteoarthritis: An Individual Patient Data Meta-Analysis of Cohort Studies

Abstract Number: 1197

Efficacy and Safety of a Single Intra-Articular Injection of MM-II, a Novel Suspension of Large, Empty, Multilamellar Liposomes, in People with Painful Knee OA: Results of a 26-Week, Phase 2b, Placebo-Controlled, Double-Blind, Randomized Trial

Abstract Number: 1198

Bicycling Is Not Associated with New Knee Pain or Disease Progression over 48 Months in Those with Knee Osteoarthritis: Data from the Osteoarthritis Initiative

Abstract Number: 1199

Association of Dipeptidyl Peptidase-4 Inhibitor Use for Type 2 Diabetes and Incidence of OA in Taiwan

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.